Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
2011536 citationsArne Astrup, Raffaele Carraro et al.International Journal of Obesityprofile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
This map shows the geographic impact of MEJ Lean's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by MEJ Lean with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites MEJ Lean more than expected).
This network shows the impact of papers produced by MEJ Lean. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by MEJ Lean. The network helps show where MEJ Lean may publish in the future.
Co-authorship network of co-authors of MEJ Lean
This figure shows the co-authorship network connecting the top 25 collaborators of MEJ Lean.
A scholar is included among the top collaborators of MEJ Lean based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with MEJ Lean. MEJ Lean is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
All Works
20 of 20 papers shown
1.
Byrne, Christopher D., Zaed Hamady, Alison K. Wright, et al.. (2020). Clinical science: Type 2 diabetes. Diabetic Medicine. 37(S1). 16–18.
Astrup, Arne, Raffaele Carraro, Nick Finer, et al.. (2011). Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. International Journal of Obesity. 36(6). 843–854.536 indexed citations breakdown →
Finer, Nick, Arne Astrup, Alex Harper, et al.. (2009). Liraglutide, a once-daily human GLP-1 analogue, reduces the prevalence of prediabetes in obese subjects over 20 weeks: a randomized placebo-controlled trial. UCL Discovery (University College London).1 indexed citations
9.
Finer, Nick, L. Van Gaal, Arne Astrup, et al.. (2009). The Once-Daily Human GLP-1 Analog Liraglutide Reduces the Prevalence of Prediabetes and Improves Systolic Blood Pressure in Obese Non-Diabetic Subjects: A 52-Week, Randomized Placebo-Controlled Trial.2 indexed citations
10.
Carraro, Raffaele, Nick Finer, Marie Kunešová, et al.. (2003). 2003 William J. Stickel Silver Award. Skin temperatures as a one-time screening tool do not predict future diabetic foot complications. UCL Discovery (University College London).2 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.